e-learning
resources
Madrid 2019
Wednesday, 02.10.2019
Granulomatous disorders: from bench to bedside
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Serious infections in sarcoidosis and the effect of treatment
M. Rossides (Stockholm, Sweden), S. Kullberg (Stockholm, Sweden), A. Eklund (Stockholm, Sweden), J. Grunewald (Stockholm, Sweden), E. Arkema (Stockholm, Sweden)
Source:
International Congress 2019 – Granulomatous disorders: from bench to bedside
Session:
Granulomatous disorders: from bench to bedside
Session type:
Oral Presentation
Number:
5160
Disease area:
-
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Rossides (Stockholm, Sweden), S. Kullberg (Stockholm, Sweden), A. Eklund (Stockholm, Sweden), J. Grunewald (Stockholm, Sweden), E. Arkema (Stockholm, Sweden). Serious infections in sarcoidosis and the effect of treatment. 5160
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Secondary pulmonary mycoses etiology agent species diversity in patients with tuberculosis and in patients with HIV infection
Source: Virtual Congress 2020 – Mechanism or pathways of chronic lung diseases
Year: 2020
The comparison of the manifestation of systemic inflammation in patients with minor forms of tuberculosis and pulmonary sarcoidosis
Source: Annual Congress 2009 - Clinical tuberculosis
Year: 2009
Non-tuberculous infections in patients with TNF-alpha-antagonist treatment
Source: Annual Congress 2011 - New aspects in prevention and treatment of community-acquired pneumonia and lower respiratory tract infections
Year: 2011
Non-tuberculous infections in patients with anti-TNF treatment
Source: Annual Congress 2010 - Treatment options for asthma
Year: 2010
The incidence of pulmonary infection caused by atypical pathogens in non-HIV immunocompromised patients
Source: Annual Congress 2010 - Unusual pathogens in respiratory infections
Year: 2010
The effect of prednisone treatment on lung function test parameters in patients with chronic sarcoidosis
Source: Eur Respir J 2002; 20: Suppl. 38, 433s
Year: 2002
The impact of patients‘ age and concomitant diseases on community-acquired pneumonia outcome
Source: Eur Respir J 2007; 30: Suppl. 51, 675s
Year: 2007
Effects of systemic steroids in patients with severe community-acquired pneumonia
Source: Eur Respir J 2007; 30: 951-956
Year: 2007
Effects of empirical antibacterial therapy on the degree of systemic inflammatory response in patients with severe community-acquired pneumonia (SCAP)
Source: Eur Respir J 2003; 22: Suppl. 45, 2s
Year: 2003
Effectiveness of treatment and correction of side effects in pulmonary MDR/XDR TB patients with concomitant liver injury
Source: International Congress 2017 – Paediatric TB: MDRTB (II)
Year: 2017
The efficacy of treatment with surfactant-BL (S-BL) in patients with destructive pulmonary tuberculosis
Source: Annual Congress 2007 - Research perspectives: diagnosis and treatment of tuberculosis
Year: 2007
Clinical characteristics and treatment response of pulmonary cryptococcosis in HIV negative patients
Source: Annual Congress 2009 - Aetiology and diagnosis of lower respiratory tract infections
Year: 2009
Impact of reducing antibiotic treatment on inflammation among patients with community-acquired pneumonia.
Source: International Congress 2019 – Prognosis in bacterial and viral pneumonia
Year: 2019
Evolution of systemic response in patients with pulmonary sarcoidosis of different course of the disease during anti-inflammatory treatment
Source: Annual Congress 2009 - Sarcoidosis in review
Year: 2009
The role of inflammatory parameters in the diagnosis and management of patients with community-acquired pneumonia
Source: Annual Congress 2012 - Management of pneumonia due to hospital pathogens
Year: 2012
Effect of corticoids on the clinical course and outcome of severe community-acquired pneumonia
Source: Annual Congress 2004 - SARS and other lower respiratory tract infections
Year: 2004
The effect of HIV-associated tuberculosis, tuberculosis-IRIS and prednisone on lung function
Source: Eur Respir J, 55 (3) 1901692; 10.1183/13993003.01692-2019
Year: 2020
Standard therapy for sarcoidosis
Source: Annual Congress 2005 - Biological agents in the therapy of sarcoidosis
Year: 2005
The role of viral and bacterial infections in asthma severity
Source: Annual Congress 2005 - PG3 - Asthma: natural history, risk factors and overall management
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept